Peptide-Based Anti-Cancer Vaccine - 16 Doses | Cellthera Clinic, Brno, Czechia

Chemotherapy and radiation primarily kill rapidly dividing cells directly. At the same time, a peptide vaccine aims to stimulate the patient’s immune system to identify and attack tumor cells, often with a different side-effect profile and a slower onset of measurable effect.

Histology confirms the diagnosis and helps determine whether the tumor expresses relevant antigens and has immune features that make vaccination more likely to be effective, which informs peptide selection and treatment planning.

Peptides are typically selected based on tumor antigen expression from pathology and biomarker testing, and sometimes on genomic findings, to target proteins present on the patient’s tumor and plausibly immunogenic.

It mainly refers to the activation of T cells, especially cytotoxic CD8+ T cells, which can directly kill tumor cells presenting the target peptide on MHC class I molecules, with support from CD4+ helper T cells.

It mainly refers to the activation of B cells and antibody production, where antibodies may help mark tumor cells for immune attack or interfere with tumor-supporting signaling, depending on the target.

A multi-dose schedule is commonly used to prime T cells and then repeatedly boost and expand them over time to build a stronger, more durable cellular immune response and immune memory.

Fewer doses may be used when the goal is to prime and boost antibody responses, supporting affinity maturation and more effective antibody production without an overly prolonged schedule.

Immune-based responses often take weeks to months to develop; some patients may show delayed benefit, and clinicians may use immune-aware response criteria alongside standard imaging and laboratory monitoring.

It can be, especially when peptides are selected based on the patient’s tumor histology, antigen expression, and sometimes tumor-specific mutations, although some vaccines target shared antigens across many patients.

Eligibility depends on whether your tumor expresses the target antigen (or has suitable neoantigens). Most commonly studied and enrolled cancers include melanoma and several solid tumors such as non-small cell lung cancer, colorectal cancer, renal cell carcinoma, hepatocellular carcinoma, pancreatic cancer, ovarian cancer, and high-grade gliomas (including glioblastoma), when biomarker and clinical criteria are met.

It is often used in combination with other therapies, such as checkpoint inhibitors, surgery, radiation, or targeted therapy, because tumors can suppress immune responses, and combination regimens may improve effectiveness.

Typical effects include injection-site pain, redness or swelling, mild fever, fatigue, headache, muscle aches, and transient flu-like symptoms; severity varies with the adjuvant and the patient’s baseline condition.

Monitoring typically includes periodic imaging, tumor markers when relevant, clinical assessment, and sometimes immune assays that measure vaccine-specific T-cell or antibody responses.

The clinic usually adjusts the schedule rather than stopping treatment; maintaining the overall dosing pattern is generally preferred, but specific decisions depend on timing, side effects, and clinical status.

Patients with uncontrolled autoimmune disease, severe immunodeficiency, specific organ transplant histories, or rapidly progressive disease requiring immediate cytoreduction may not be ideal candidates, depending on the protocol and physician judgment.

Peptide-Based Anti-Cancer Vaccine - 16 Doses | Cellthera Clinic, Brno, Czechia is rated as 9.50 by AiroMedical.

The provider is Prof. MUDr. Jaroslav Michalek, Ph.D.

The offer is designed for 14 days.

No, Peptide-Based Anti-Cancer Vaccine - 16 Doses | Cellthera Clinic, Brno, Czechia is an outpatient deal.

AiroMedical gallery has 6 photos related to Peptide-Based Anti-Cancer Vaccine - 16 Doses | Cellthera Clinic, Brno, Czechia.

The offer is eligible for both adults and kids.

Yes, the components of the deal can be changed. Get in touch with a vendor to create a personalized proposal.

Peptide-Based Anti-Cancer Vaccine - 16 Doses | Cellthera Clinic, Brno, Czechia has 13 add-ons and unique AiroCare services for AiroMedical users.